Psychedelic distress: here’s what a helpline caught

Clinical takeaway: Treat a hard experience with cannabis, ketamine, or a psychedelic as seriously as any other, since distress can look similar across substances and ran higher during an experience than afterward.

Most psychedelic use happens at home, at festivals, and in ceremonies, so people who hit trouble usually reach out to a peer rather than a clinician. As Oregon and Colorado build regulated frameworks that widen psychedelics access, clinicians and policymakers are working with little data on who struggles, when, or on which drugs.

Festival reports offer snapshots tied to a single event, and the everyday calls people place when an experience turns difficult have gone largely unexamined. This descriptive analysis of one US peer support line puts numbers on that ground, including who calls and what they report.

Nearly half of calls from people in the midst of an experience involved distress, against just over one in three calls from people seeking support afterward. So, timing actually separated out distress level more than the drug type did. Within each group, the substances did not differ significantly.

Pooled across both groups, cannabis showed the highest distress rate at 47.2%, with the other major substances at roughly 41% to 42%. That difference largely traced to when callers got in touch: about seven in 10 cannabis callers contacted the line during an experience, against fewer than four in 10 callers reporting ketamine or MDMA (methylenedioxymethamphetamine). Calls escalated to 911 or 988 in under 1% of interactions related to each major substance.

The analysis drew on 25,419 interactions from April 2021 to February 2026 on the Psychedelic Support Line, a phone and text service run by the nonprofit Fireside Project and answered by trained volunteers. Volunteers coded each call, and substances were recorded for about six in 10, among them cannabis, which is not a psychedelic. Cannabis accounted for about one in eight substance-coded calls. With a far larger pool of users than psilocybin, even a low crisis rate per user would send many distressed people to the line.

“Clinical trials have taught us an enormous amount about psychedelics under controlled conditions, but they are only a small fraction of how these substances are actually being used,” said Felix Schoeller, PhD, director of Fireside Lab at Fireside Project and lead author of the study. “The goal of this resource is to make the real-world landscape more scientifically tractable, from epidemiology and safety monitoring to the study of what effective psychological support actually looks like.”

Source: Schoeller F, et al. (2026 Oct 30) Sci Adv. The Fireside Database: Large-scale evidence from 25,419 psychedelic support interactions